ENCell’s EN001 Receives Orphan Drug Designation from the US FDA for Charcot-Marie-Tooth Disease

ENCell announced that its investigational drug EN001 has been granted Orphan Drug Designation by the US FDA for the treatment of Charcot-Marie-Tooth disease. EN001 is a MSC therapy that enhanced cell longevity and optimized the secretion of therapeutic molecules required for treatment.